Purpose: In locally advanced (uT 3 , N + ) adenocarcinomas of the esophagus, neoadjuvant chemotherapy improves patient outcome. However, only a subgroup of patients responds. Therefore, in the present study, we evaluated whether the response to neoadjuvant chemotherapy can be predicted by a pretreatment tumor biopsy analysis.
It has been shown that the incidence of esophageal adenocarcinoma is increasing at an alarming rate in Western countries (1) (2) (3) . In spite of endoscopic surveillance programs for Barrett's metaplasia, early stage cancer is discovered in only about 10% according to the international literature (4) . More than 50% of patients present with locally advanced disease (5) (6) (7) . In these patients, neoadjuvant chemotherapy seems to increase the chance for a curative resection and enhance survival in responding patients (8) (9) (10) (11) . Unfortunately, Barrett's carcinoma shows a very heterogenous behavior in progression and response to neoadjuvant chemotherapy. Response occurs in only 50% of patients after chemotherapy with cisplatin, 5-fluorouracil, and leucovorin. If patient outcomes could be predicted accurately, treatments could be tailored individually to avoid chemotherapeutic-induced side effects in nonresponding patients. Therefore, the aim of this study was to differentiate responders from nonresponders even before starting a neoadjuvant therapy on the basis of tumor biopsies using microarray analysis and immunohistologic staining.
Patients and Methods
From September 2006 to January 2008, 47 patients underwent neoadjuvant chemotherapy with cisplatin, 5-fluorouracil, leucovorin and subsequent esophagectomy for adenocarcinoma of the distal esophagus at our department.
All patients had tumors located in the distal third of the esophagus within areas of specialized intestinal-type columnar epithelium (Barrett's esophagus). In the primary staging, all 47 patients showed a locally advanced cancer with infiltration of all esophageal layers (uT 3 -category). Eighty-one percent of these patients showed enlarged locoregional lymph nodes in the primary endosonography or computed tomography scan. The term locally advanced refers to the above mentioned tumor stage, meaning uT 3 , N 0/+ .
Preoperative diagnostic work-up included gastroscopy, endosonography, biopsy of the primary tumor, computed tomography scan, and a risk assessment concerning the operability of the patient. Routine laparoscopic staging was not done in these patients. The chemotherapy protocol was comprised of two cycles of 5-fluorouracil and cisplatin for 6 wk. Eighty-nine percent of our patients completed the neoadjuvant regimen. The remaining patients did not complete the chemotherapy due to toxicity of the regimen used. Currently, chemotherapy alone is the standard therapy regimen in the neoadjuvant setting. To analyze a homogeneous group of patients, only patients receiving the above mentioned chemotherapy regimen were included.
Afterwards, all patients underwent an abdominothoracic resection. A D2 lymph node dissection was routinely done. In the chest, the lymphadenectomy included the periesophageal and infracarinal nodes. In selected patients, a lymph node dissection extended to the apex of the right chest was done. This was the case where suspicious nodes were observed in the apex during the inspection. The tumors were staged according to the guidelines of the International Union against Cancer 1997. The response rate after neoadjuvant chemotherapy was assessed according to Becker by comparing the pretreatment biopsy with the surgical specimens. Patients with <50% viable tumor cells were defined as responders.
Two biopsies of each patient from primary staging were used for further examinations to differentiate responders from nonresponders. Tumor samples were snap frozen in liquid nitrogen. All samples were reviewed by an experienced pathologist and estimated to contain at least 70% tumor cells with an average of 86%. The samples were used for microarray analysis and immunhistology (IHC). The results were correlated with the histopathologic workup of the surgical specimen with staging, grading, and response evaluation. The study was Institutional Review Board approved.
RNA extraction. Tumors of 10 patients were homogenized and RNA was isolated using Rneasy Mini kit (Qiagen). cRNA preparation was done, purified on Rneasy Columns (Qiagen), and eluted in 55 μL of water. Fifteen micrograms of cRNA were fragmented for 35 min at 95°C, and double-strand cDNA was synthesized with a oligo (dT)-T7 primer (Eurogentec) and transcribed using the Promego RiboMax T7-kit (Promego) and Biotin-NTP labeling mix (Loxo).
Microarray experiments. cRNA was mixed with B2 control oligonucleotide, eucaryotic hybridization controls (Affymetrix), hering sperm (Promega), buffer, and bovine serum albumin to a final volume of 300 μL and hybridized to one microarray chip (Affymetrix) for 16 h at 45°C. Washing steps and incubation with streptavidin (Roche) biotinylated goat anti-streptavidin antibody (Serva), goatIgG (Sigma), and streptavidin-phycoerythrin (Molecular Probes) were done in an Affymetrix Fluidics Station. The arrays were than scanned with an Affymetrix scanner and the digitized image data were processed using the Affymetrix Microarray Suite 5.0 software.
Data preprocessing. All Affymetrix U133 GeneChips passed quality control to eliminate scans with abnormal characteristics. Background correction and normalization were done in the R computing environment. Background-corrected and normalized expression measures from probe level data (CEL files) were obtained using the robust multiarray average function implemented in the Bioconductor package affy.
Image data from each microarray were individually scaled to an average intensity of 150. The data were then filtered to a fold change of 2.5. Scaled average difference value and absolute call data were exported to flat text files and used for numerical analysis. Significance analysis was done with the SAM multiclass algorithm. Genes that were differentially expressed among all experimental groups were identified by setting the significance level to a false discovery rate of <0.1. Comparing the mean expression levels of the groups, the threshold level was set at >2 and <0.5-fold differences.
Hierarchical clustering using Euclidean distance and kmeans clustering using centroid-based search for similarity measurement was done with the program Spotfire Decision Site 7.1, based on z score-normalized expression values (subtraction of mean and division by SD).
Mann-Whitney's U test was done to extract genes that were differently expressed between the responding and the nonresponding patient groups.
Immunhistology. For IHC, snap-frozen sections were embedded and sliced at 5 μm thickness onto positively charged slides. The sections were incubated in 3% H 2 O 2 and then blocked for unspecific binding in 1% goat serum. Then, sections were incubated in the primary monoclonal antibody overnight at 4°C (anti-Ephrin Receptor B3 1:100; H2049-M01, Abnova). After immersing in PBS the following day, the sections were then incubated with the biotinylated secondary antibody (1:200; Vector Laboratories). Sections were then rinsed and treated with avidin-biotin complex (Dako kit K5007). Sites of antibody binding were visualized with diaminobenzidine (Sigma). Finally the sections were immersed in hematoxylin solution for 1 min. As positive controls, we used sections from a healthy esophagus that was also snap frozen and treated
Translational Relevance
The presented article shows that by taking a biopsy of an esophageal adenocarcinoma, the prediction of response to neoadjuvant therapy may be possible. This could ultimately change the current concepts of multimodal therapy in these patients. Patients who do show a microarray pattern suggesting response will receive the standard neoadjuvant chemotherapy, whereas the remaining patients will be included in newly designed targeted therapies or go immediately to surgery.
equally. Negative controls were obtained by omitting primary antibody in the procedure.
For further IHC studies, anti-human Ki-67 (clone MIB-1, 1:100, Dakocytomation) was used. The corresponding secondary antibody were from Molecular Probes (Invitrogen). Sections were stained using Vectastain ABC peroxidise kit (Vector Laboratories) and counterstained with hematoxylin. For negative control, the primary antibody was again omitted.
Statistics. Comparison of numerical data was done with the Student's t test. Comparison of IHC results and the histologic results were done with the Fisher's exact test. The threshold of statistical significance was set at 0.05. Statistical analysis was done using SPSS 14,5 for windows (SPSS).
Results
Patient and tumor characteristics. Demographic information of the study population is summarized in Table 1 . Responders and nonresponders to neoadjuvant therapy were similar with respect to age and sex. Age ranged from 41 to 84 years (mean, 60.8 years); 39 were male, 8 were female.
Neoadjuvant treatment was completed in 42 of 47 patients (89%). The other five patients received a reduced chemotherapy because of grade III or IV toxicity. In this small group, a significant relationship between response and reduction of the chemotherapy could not be found.
The final histologic work-up and the histologic response evaluation of the surgical specimen after neoadjuvant chemotherapy is presented in Table 2 . In most cases, all wall layers were involved (T3-category) and positive lymph nodes could be found (55.3%). In one patient, an initially unknown liver metastasis could histologically be proven. The majority of our patients showed a good response rate with <50% viable tumor cells after neoadjuvant chemotherapy.
Postoperative morbidity and mortality did not show a significant difference in responding and in nonresponding patients. Out of 47 patients, one died as a consequence of anastomosis insufficiency, sepsis, and multiorgan failure. Four patients had anastomosis insufficiencies with adjacent abscesses that needed drainage and one chylothorax needing reoperation. The other 41 patients had a regular postoperative course.
The statistical analysis of the microarray results showed 86, at least 2-fold, significantly differentially expressed genes between responding and nonresponding patients.
Forty-four genes were downregulated and 42 were upregulated ( Figs. 1 and 2 ). To validate some of the results of the microarray analysis, we looked for genes that were highly overexpressed or underexpressed. The 86 genes coded for proteins involved in all cell compartments especially for the cell cycle regulation, gene expression, signal transduction, cytoskeleton, and transcription. The predominant upregulated genes (Fig. 2) in responding patients were apoptotic-associated genes, tumor suppressor genes (p53), genes involved in cell-cell interaction (vasoactive intestinal peptide receptor, tumor necrosis factor-α-induced protein 8), the cytoskeleton, and transmembrane receptors, e.g., the Ephrin B3 receptor, showing the strongest difference in the gene expression rate between responding and nonresponding tumors.
IHC against the Ephrin B3 receptor was done to examine Ephrin B3 receptor protein production. A strong membrane-bound immunostaining could especially be found in chemotherapy-responding tumors. Figure 3 shows a well-differentiated Barrett's carcinoma with an HE staining and an immunohistology. Interestingly, one can find the immunostaining especially in the tubular such as structures with a clear cut boundary to the connective tissue. Table 3 shows the statistical results of the IHC. A statistical significance could be found for depth of invasion, lymph node metastases, grading, and chemotherapy response.
Discussion
A multimodal therapy concept in patients with locally advanced Barrett's carcinoma is still under discussion, because many studies have shown that only patients who respond to a neoadjuvant chemotherapy have a survival benefit (9) (10) (11) . In these patients, a neoadjuvant therapy results in a downsizing and a downstaging of the tumor. A complete response can be achieved in up to 16% of patients without any residual tumor in the resection specimen (12, 13) . Another 40% of patients show a good response with <50% viable tumor cells in the postoperative histologic work-up according to Becker and a positive effect on the lymph node involvement, one of the most important prognostic factors (14, 15) . However, almost 50% of the patients are treated with only very little effect Several studies showed that with positron emission tomography scans in the beginning and after 2 weeks of chemotherapy, the response rate can be evaluated and patients without any response can be identified and accordingly be conducted to a different therapy (16, 17) . Thus, an individualized therapy concept and the prevention of adverse effects and a higher morbidity in nonresponding patients seems to be possible.
To find the reason for responding and accordingly nonresponding tumors, to describe the different tumorbiology, and maybe even be able to differentiate these two cohorts of patients, we performed a micorarray analysis in patients with a locally advanced Barrett's carcinoma all undergoing a neoadjuvant chemotherapy with cisplatin, leucovorin, and 5 fluorouracil and a following resection.
Microarray analysis have often been done for other tumor entities especially for gynecological tumors, but also in colon and gastric cancer to describe the tumorigenic process (18, 19) . In these studies, the microarray results of healthy mucosa was compared with cancerous epithelium (20) . The comparison of the genetic fingerprint of responding versus nonresponding Barrett's carcinoma has never been done before.
With our analysis, we could characterize 86 genes playing a role for tumor response to neoadjuvant chemotherapy. Interestingly, these genes are not only regulating the cell cycle, transcription, and gene repair, but also encode for signal transduction, the cytoskeleton, and surface-bound tyrosine kinase receptors. Hence, we found a panel of upregulated and downregulated genes that were expressed differently between responding and nonresponding tumors. With these results, we cannot tell which of these genes play a direct role for a good response rate. However, our results show that in the future microarray analysis, a small gene panel of <100 genes might be able to predict chemosensitivity already during primary staging.
The gene encoding the Ephrin B3 receptor had the strongest difference in the gene expression rate with an upregulation of its RNA. To examine also the protein level of this tyrosin kinase receptor, we performed an IHC. Ephrin receptor tyrosin kinases and their ligands have primarily been described in the nervous system for their roles in axon guidance, development of the central nervous system, cell intermingling, and tissue morphogenesis (21) (22) (23) (24) (25) (26) . In the gastrointestinal tract, the important consequences of Eph/EFN signaling are morphogenesis, tumorigenesis and metastatic potentials, angiogenesis, and tumor vasculature (27, 28) . Recent data suggests that Eph/EFN signaling system could play an important role in the development of novel inhibition strategies and cancer treatments to potentially target the receptor tyrosine kinase and/or its ligand (27, 28) . Ephrin B2 and B3 is expressed in intestinal proliferating cells depending on the WNT/β-catenin signaling pathway (27) . Eph/EFN and WNT signaling pathways network together during embryogenesis, tissue regeneration, and carcinogenesis; however, direct transcriptional regulation of EFN family members by the WNT/β-catenin signaling pathway remains unclear (27) .
The protein has been suggested to regulate proliferation and differentiation. The tyrosin kinase also seems to influence growth, migration, and invasion of various normal and malignant cells (27) .
To date, few reports have examined expressions of Ephrins and their ligands in espohageal squamous cell cancer (28) (29) (30) . There is no report examining the expression pattern of the Ephrin signaling system in adenocarcinoma of the esophagus, especially comparing tumors responding to chemotherapy versus nonresponding tumors.
In the present study, there were correlations between the Ephrin B3 receptor expression on RNA level and in the IHC on protein level and the chemotherapy response. The IHC could show a significant correlation to lymph node metastasis, depth of tumor invasion, and grading. The positive correlation between the IHC of the Ephrin B3 receptor confirms the results of the microarray analysis on a protein level. Thus, we could find a new potential biomarker for the prediction of chemotherapy response in patients with Barrett's carcinoma. Because the Eph expression is regulated by the WNT signaling pathway, which plays an important role in chemotherapy response, the Eph may only be an indicator for response, but not the reason. This question cannot be answered thus far from our results yet. However, our results confirm the correlation of local invasion, lymph node metastases, and differentiation of the tumor with Eph receptor expression as it could already been described in patients with squamous cell cancer of the esophagus (28) (29) (30) (31) .
In conclusion, our results suggest that it could be possible to characterize patients responding to chemotherapy before starting the treatment using customized microarray analysis. Ephrin B3 receptor seems to play an important role in cell sorting, cell intermingling, and migration and therefore may serve as an important new biological tumor marker for local invasion and chemotherapy response. As it is known from other tumor entities, the Ephrin receptor tyrosin kinase correlates with local invasion, lymph node involvement, and grading. Further examinations are necessary to evaluate these results and a possible therapeutic utility.
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